Replies to post #122714 on Biotech Values

[ghmm]

I can't think of a good example off-hand but have wondered what if one product (same mechanism) had better safety/tolerability or was more convenient either via dosing or route of administration. Could it break Orphan exclusivity?

[mcbio]

In Incyte's case, the drugs are different, so you and AF are correct that there is no protection based on Orphan.

Both the INCY and YMI drugs are JAK1/JAK2 inhibitors I believe. But, I assume you're saying that they are still different chemical structures.